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Available online 14 June 2016Treatment of cancer is becoming increasingly personalized and biomarkers continue to be developed to reﬁne
treatment decisions. TumourmRNA abundance data is commonly used to develop such biomarkers, often to pre-
dict patient survival. However, survival analyses present unique challenges and it is unknownwhether analysing
mRNA abundance information in a discrete or continuous manner yields different results. To address this, we
analysed 1988 primary breast tumour transcriptomes. When compared univariately, approximately 60% of all
genes showed differences between the discrete and continuous Cox proportional hazards models with q-value
differences spanning four orders of magnitude for some genes. Further, hybrid models using both continuous
and discrete data used to classify poor prognosis via random forest outperformed models using a single type
of information. Thus some genes appear to continuously contribute to poor prognosis while others display
threshold effects, and incorporating this into biomarker development is a key unexplored avenue.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Biomarkers1. Background
Survival analyses associate patient outcome with one or more
biologically descriptive variables. Typical goals of such studies are to
evaluate the impact of a treatment or intervention on patient survival
over time, relative to a control group. Alternatively, they can be used
to generate models that can predict for any individual what their base-
line risk of a later adverse event will be. These analyses are often much
more statistically complex than simple linearmodels because of cases in
which patient information in incomplete (i.e., the data is censored).
Censoring can occur for many reasons, including if the event of interest
did not occur within the period of study (e.g. the patient is still alive at
the end of the observation interval) or if a subject withdraws from
the study prior to completion. In such a case, the information is right-
censored and the minimum survival time is known. As a result several
statistical methods have been created to handle right-censored infor-
mation, including the discrete Cox proportional hazards (PH) model
(also known as the log-rank test) [1] and the continuous Cox PH
model [2].
Both the continuous and discrete versions of the univariate Cox PH
model are routinely used to analyse data generated from survival stud-
ies [3]. Their null hypothesis is that the probability of an event occurringity Avenue, Suite 510, Toronto,
.
. This is an open access article underis not different between the populations being compared [1]. Both
models make the same assumptions: that censoring is not related to
prognosis, that the probability of survival is not signiﬁcantly different
for individuals recruited early and late in the study, and that the events
happened at the speciﬁed times. Recent studies relating to gastric
cancer [4], ovarian cancer [5], and lung cancer [6] provide examples of
analyses utilizing the discrete Cox PH model. Other work examining
gastric cancer [7], ovarian cancer [8], and breast cancer [9] have used
the continuous Cox PH model.
While these models are widely used, continuous and dichotomized
analyses of the same information may capture different underlying
biological phenomena. For example, in some cases it is clear that a
biological variable can be accurately discretized, e.g., copy-number aber-
rations. Further, categorising quantitative information into two groups
can also assist with removing batch effects and standardizing datasets.
In contrast, biological processes that are sensitive to absolute values
(e.g., hormone levels [10]) may be better represented by analysing the
data in a continuous fashion.
Fundamentally, then, these twomodels represent different expecta-
tions about the biology and underlyingmechanism of action of the gene
being studied. Consider mRNA abundance data, which is widely used to
generate prognostic models for personalizing patient therapy. The
continuous model assumes that each additional mRNA molecule in a
cell incrementally increases or decreases the risk of an event, while
the discrete model suggests that an effect is not observed until some
key threshold of mRNA abundance is reached. Surprisingly, then, tothe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Experimental design. Raw mRNA abundance ﬁles from the Metabric breast cancer
dataset were preprocessed, summarized and quantile-normalized. 1988 breast cancer
patients with primary breast tumours were divided into training and validation groups.
The Coxdiscrete and Coxcontinuous models were applied to subjects in the training group to
generate q-values and to assess differences between models. The 2000 most signiﬁcant
genes identiﬁed by each model were selected for further analyses. From this pool, genes
were randomly selected to build random forest classiﬁcation models and predict
survival. The validation group was used to independently validate each of the 40 million
permutations for each of four models used.
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data employ either the discrete (Coxdiscrete) or the continuous
(Coxcontinuous) models for all genes. We are unaware of any systematic
efforts to determine which approach better represents individual
genes, nor to assess if biomarkers comprised of a mixture of continuous
and discrete features will be more accurate.
To address this gap in the ﬁeld, we examined the mRNA abundance
information for 1988 breast cancer patients with primary breast
tumours from theMetabric study [11]. In particular, we provide biolog-
ically relevant examples for which the Coxdiscrete and Coxcontinuous
models produce contrasting results (i.e., the q-value from one model is
high while the q-value from the other model is low). In addition, we
provide insight into the performance of each model independently, or
in combination, in the context of predicting patient survival via a
random forest classiﬁcation analysis.
2. Results
2.1. Experimental design
This study used the Metabric breast cancer dataset which contains
survival and mRNA abundance information from over 19,000 genes
for 1988 primary breast tumours. Our study involved two major parts
(Fig. 1). First, we applied the Coxdiscrete and Coxcontinuous models sepa-
rately to the Metabric training dataset (996 subjects). False-discovery
rate adjusted p-values (referred to as q-values henceforth), were
compared to assess and quantify differences between the models. This
dataset was well powered to assess such differences (Fig. S1). Next,
we evaluated the impact of these models on multi-gene biomarkers
by considering the top 2000 genes implicated by each model (i.e., low
q-values), resulting in a pool of 2759 unique genes. We assessed the
null distribution of biomarker space by randomly selecting genes from
this pool for modelling via a random forest classiﬁer [12]. Each random
forest model was independently validated using a validation dataset
containing data from 992 subjects.
2.2. Overview of differences between models
We assessed the univariate, gene-wise differences between the q-
values generated from the two models (Fig. 2). Amongst examined
genes, two broad cases exist: those genes for which the two models
agree and those for which they disagree. The ﬁrst case includes genes
that generated a high q-value via both the Coxdiscrete and Coxcontinuous
models as well as genes for which the two models generated a low
q-value. The second case – genes for which the models generated
very different q-values – was surprisingly common. Overall, q-values
from the Coxdiscrete and Coxcontinuous models were not highly correlated
(Spearman's ρ = 0.68). Only 62% (12,318/19,877) of q-value differ-
ences were less than or equal to 0.2, demonstrating that substantial
differences in q-values exist for a large subset of the dataset. Some of
the differences for individual genes were very large, such as NUDT19
with qcontinuous = 2.5 × 10−6 and qdiscrete = 0.012 while HK3 exhibited
qcontinuous = 0.25 and qdiscrete = 0.0025. Overall, the continuous model
tended to yield smaller q-values, as might be expected from its greater
statistical power.
2.3. Functional consequences of model differences
Genes demonstrating the largest discrepancies between the
Coxdiscrete and Coxcontinuous models were identiﬁed for further analysis.
To probe the functional roles of these genes, a pathway analysis was
completed using the GoMiner software [13] (Table S1). Pathway analy-
sis revealed that genes with the largest q-value differences between
models (n = 30) were particularly enriched for cellular component:
chromosome (GO:0005694).Of the genes showing the largest differences between the two
models, the Coxcontinuous q-values were typically lower than those
from the Coxdiscretemodel (Table 1). This is of particular interest as a sur-
vival analysis using the Coxdiscrete model may not identify and investi-
gate these genes, potentially missing biologically relevant information,
despite its wide use in biomarker development studies. The mRNA
abundance of those genes with large q-value differences between
Fig. 2. Overview of q-value differences. Q-values from the Coxdiscrete and Coxcontinuous
models were similar for a large number of genes (points along the x = y line,
Spearman's rho = 0.68). A small subset of genes were identiﬁed as signiﬁcant via only
one model; labelled points highlight examples of these genes.
Fig. 3. Permutation analysis. mRNA abundance was compared using Spearman's
correlation coefﬁcient for randomly selected pairs or pairwise for genes with the 10
largest q-value differences between models. mRNA abundance amongst the top 10
genes demonstrated only a slightly higher correlation as compared to 1 million
randomly selected gene pairs.
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Spearman's ρ± SD: 0.2 ± 0.1) as compared to random pairs of genes
(mean ρ±SD: 0.0± 0.1; Fig. 3), suggesting that we are not considering
a single well-correlated transcriptional group, but rather a series of in-
dependent events. In fact, amongst the genes with the 10 largest differ-
ences in q-values between models, the largest correlation was detected
between the mRNA abundance of GPI and ENO1 with Spearman's ρ of
only 0.48 (Fig. S2). Further, a q-value sensitivity analysis demonstrated
that this was a broader pattern across the dataset (Fig. 4), with a sub-
stantially higher percentage of genes with lower Coxcontinuous q-value
than a Coxdiscrete q-value for all q-value difference thresholds. Thus
discretization clearly sacriﬁces statistical power for most, but not all,
genes.
2.4. Impact on prognostic signature generation
Since the Coxdiscrete and Coxcontinuous models describe different
underlying biological phenomena, we hypothesized that models using
both discrete and continuous information would outperform modelsTable 1
Examining large q-value differences.
A subset of genes were associated with large differences in q-values between the
Coxdiscrete and Coxcontinuous models; the top 12 examples include genes such as NUDT19
and CA-9. Genes are sorted by the largest q-value differences.
Gene qdiscrete qcontinuous
NUDT19 0.01321 2.37 × 10−06
LCT 0.32071 8.05 × 10−05
GSK3β 0.00426 1.28 × 10−06
FAM91A1 0.37831 3.38 × 10−04
LSR 0.01130 1.02 × 10−05
CATSPERβ 0.05235 6.46 × 10−05
CA9 0.20538 3.38 × 10−04
ENO1 0.05536 9.48 × 10−05
GPI 0.00071 1.28 × 10−06
RGS9BP 0.05673 1.23 × 10−04
CST3 0.01490 3.24 × 10−05
GARS 0.00252 6.18 × 10−06using only discrete or continuous information alone. To address this,
we utilized machine learning techniques as these have previously
proven useful in answering similar questions [14–17]. A random forest
classiﬁer was trained on the training dataset (996 subjects) and usedFig. 4. Q-value sensitivity analysis. A q-value sensitivity analysis was performed to reveal
the percentage of genes meeting or exceeding various cutoff thresholds for differences in
q-values. Information regarding which model predicted a lower q-value is preserved –
blue points represent cases in which the Coxcontinuous model generated a lower q-value
while orange points represent cases where the Coxdiscrete model produced lower
q-values.
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ignored). Genes with the lowest q-values from the Coxdiscrete and
Coxcontinuous models were selected (2000 genes per model, leading to
a ﬁnal pool of 2759 unique genes). From this pool, subsets of either 50
or 100 genes were randomly selected to build a random forest classiﬁer
with discrete data, continuous data, or a mix of discrete and continuous
mRNA abundance information. In this way we sampled the null distri-
bution of biomarkers with both model characteristics, allowing us to
draw general conclusions, as has been done previously for other similar
questions [14–17].
Four separate types of models were created to predict patient sur-
vival and were independently validated using the validation cohort
(992 subjects). The nature of the mRNA abundance information in the
fourmodels was as follows: i) 100 genes with only continuous informa-
tion, ii) 100 genes with only discrete information, iii) 50 genes with
both continuous and discrete information, and iv) 50 geneswith contin-
uous information and 50 other geneswith only discrete information. For
each model, 40 million permutations were carried out, with each per-
mutation using a random set of genes.We note that this type of analysis
is sampling a small, but representative, fraction of the total space of
~19,00050 total possible multi-gene signatures, and each permutation
represents a distinct view of patient biology. To analyse the predictive
power of these different biological representations, the models were
compared using the area under the receiver-operator curve (AUC).
The curve for each of the four models is representative of the spread
of AUC values associated with 40 million permutations for each model
(Fig. 5).
The most interesting region in these curves is the tail because this
portion of each curve represents permutations that generated the
highest AUC values for a particular model. Models using both discrete
and continuous information generated classiﬁcation models that
were superior to those generated using only discrete or continuous
information (see particularly the long purple tail in the inset of Fig. 5).
We further validated the hybrid approach using the Hatzis breast
cancer dataset. Again, models using continuous and discrete data
outperformed models using only continuous or discrete data (Fig. S3).
This reinforces the value of simultaneously considering data in a contin-
uous and discrete manner.
To further illustrate the value of using continuous and discrete
informationwe created onemillion signatures, each of which contained
100 random genes from the pool of 19,877 genes. Analysis of theseFig. 5. Random forest classiﬁcation analysis. Four models were used to predict patient surv
information (orange), ii) 100 genes with discrete information (green), iii) 50 genes with conti
information and 50 other genes with discrete information (yellow). For each of the models,
AUCs. Model iv) outperformed all other models.signatures demonstrated that the Coxcontinuous model was associated
with lower q-values for an average of 64 ± 5 genes (mean ± SD),
highlighting the potential of both models (Fig. 6). Better performance
bymodels using different types of informationmaybe related to the dif-
ferent underlying biology that discrete and continuous models capture.
Accordingly, by assessingmRNA abundance data inmore than oneway,
a wider array of information is represented in a biologically relevant
manner, producing better classiﬁcation models.3. Discussion
Survival analyses are routinely used to relate biologically descriptive
variables to patient outcome. In particular, the Coxdiscrete and Coxcontinuous
models are often used as they can handle many of the complexities of
survival data. Despite being widely used, a comprehensive study into
the ability of these models to capture different underlying biological
phenomena has yet to be reported.
In breast cancer, these two models can produce q-values that are
signiﬁcantly different for the same gene. Differences between these
methods can be problematic as some analyses use only one model and
may thus confound the biological interpretation of results. For example,
carbonic anhydrase 9 (CA-9) is associated with tumour hypoxia and
malignant breast cancer [18]. However, CA-9 had the seventh largest
q-value difference amongst the examined genes, being highly signiﬁ-
cant in the Coxcontinuous model (qcontinuous = 3.4 × 10−4) but not in
the Coxdiscrete model (qdiscrete = 0.21). Understanding the basis of such
discrepancies will allow future analyses to exploit these models and
carry out more informed survival studies.
Understanding if a gene should be modelled in a continuous or
dichotomized manner will be crucial for the development of more
accurate biomarkers. Determining the best way to model the impact
of a gene on survival will also provide insight into the underlying
biology of that gene in relation to the disease. This will help elucidate
the context in which that gene impacts survival. When the impact of a
gene on survival is more accurately modelled by the Coxdiscrete model,
we learn that the gene only becomes relevant to disease after a particu-
lar threshold. In contrast, when the interplay between a gene and
survival is modelled more accurately by the Coxcontinuous model, we
expect each additional mRNA molecule related to that gene to have an
impact on patient survival. Overall, by looking at which model providesival. The type of information in each model is as follows: i) 100 genes with continuous
nuous and discrete information for each gene (purple), and iv) 50 genes with continuous
40 million permutations were carried out and a density curve was used to visualize the
Fig. 6.Onemillion signatures of 100 random genes. Onemillion signatures of 100 random
genes illustrated that the Coxcontinuous model was associated with lower q-values for an
average of 64 ± 5 genes (mean ± SD). This highlights the need for the use of hybrid
models in biomarker development that can incorporate information in a continuous and
discrete manner.
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survival, we can learn about the biology of that gene.
We also used a random forest classiﬁcation analysis to predict
patient outcome by using discrete, continuous, or hybrid models. It is
important to note that each permutation in the random forest analysis
is a unique representation of patient biology. The predicted survival
times are calculated within the context of the randomly selected
genes for a given permutation. Furthermore, hybrid models using
discrete and continuous information predict survival with respect to
the randomly selected genes and the nature of the data for each gene
(i.e., discrete or continuous mRNA abundance information).
The most accurate translation of mRNA abundance information into
a prediction of survivalwas achieved by amodel using discrete and con-
tinuous information. Indeed in signatures with 100 random genes ap-
proximately 64% of the genes provided more valuable information if
examined continuously while approximately 36% were more helpful
when assessed in a discrete manner. In an ideal model all randomly
selected genes that are more informative in their discrete nature
would be analysed as such, while the remaining genes would be
analysed in a continuous fashion.
These results provide direction to the community of researchers ac-
tively developing biomarkers. Extensive efforts have been devoted to
accurately pre-processing genomic data [19,20], developing robust
modelling techniques for biomarkers [21] and integrating pathway-
based information [22,23] into biomarker development. However, bet-
ter feature engineering of the raw data used to develop biomarkers
has been largely ignored. Indeed we have only focused on the most
common biomarker dichotomization approach: separation of groups
around the median. It may be that alternative dichotomization strate-
gies will provide further additional value. Further, the interaction
between different machine-learning methods and the characteristics
of the input features remains to be elucidated, providing further oppor-
tunities for improvements in biomarker discovery algorithms.
4. Conclusions
The Coxdiscrete and Coxcontinuous models are commonly used tools for
the analysis of survival data. While the models may broadly agree in
some instances, cases where they disagree are of particular interest
because survival analyses typically only employ one model. In such
cases, it is important to understand what potential ﬁndings may not be
uncovered by failing to use a particular statistical model. Additionally,the random forest classiﬁcation analysis demonstrated that models
capturing discrete and continuous information outperform models
using only discrete or continuous data.
5. Methods
5.1. Data pre-processing
RawMetabric breast cancer dataset ﬁles [11] were downloaded from
the European genome-phenome archive (Study ID: EGAS00000000083).
Data was pre-processed, summarized and quantile-normalized from raw
abundance ﬁles generated via Illumina BeadStudio (R packages:
beadarray (v2.4.2) and illuminaHuman (v3.db_1.12.2)). At the time of
our analysis dataﬁles fromone subjectwerenot available andaccordingly
excluded, resulting in a total of 1988 subjects. This dataset was divided
into a training cohort (n = 996) and a validation cohort (n = 992) for
subsequent analyses.
5.2. Survival analyses and model comparison
For analysis using the Coxdiscretemodel,mRNAabundancewasmedian
dichotomized for each gene across all samples from the training cohort
and subjects were labelled as having either high or low abundance. For
the Coxcontinuous model, abundance information was unrestricted
and could exist as any value over a continuous range. Using each model,
p-valueswere generated for each gene. A false-discovery rate adjustment
was applied to these p-values to generate q-values. These q-values were
used to compare the two models; the difference in q-values between
the Coxdiscrete and Coxcontinuous models for each gene was used as the
metric of interest for data analysis. Gene annotations were extracted
from Entrez Gene (Accessed June 14, 2015) [24].
5.3. Random forest classiﬁcation analysis
50-gene and 100-gene random forest classiﬁcation analyses were
performed using the randomForest package (v4.6-10) and survival
package (v2.38-3) for R (v3.2.1). The 2000 most signiﬁcant genes from
the Coxdiscrete and Coxcontinuous models were selected (4000 genes
total, consisting of 2759 unique genes). From this pool, 50 or 100
genes were randomly sampled without replacement to build a random
forest classiﬁer with either discrete, continuous, or amix of discrete and
continuous mRNA abundance information.
The nature of themRNA abundance information for the four models
was as follows: i) 100 genes with continuous information, ii) 100 genes
with discrete information, iii) 50 geneswith continuous and discrete in-
formation for each gene, and iv) 50 genes with continuous information
and 50 different genes with discrete information. In model ii), mRNA
abundance was median dichotomized for each of the 100 randomly
selected genes to attribute a high or low value to each gene for each
patient. For model iii) mRNA abundance data was both median dichot-
omized andpreserved as a continuous variable for 50 randomly selected
genes (resulting in 100 features). In model iv), mRNA abundance was
median dichotomized for 50 randomly selected genes while mRNA
abundance data for 50 separately selected random genes was also
used in the input. These analyses used event status (irrespective of
time) as the input for classiﬁcation. For each of the four models, 40
million permutations were carried out to generate a classiﬁer that
predicts survival.
Each classiﬁer consisted of 501 trees with anmtry value 10. With 40
million permutations for each model, 501 trees for each permutation
should provide sufﬁcient variability within each model to produce
representative AUC values. Models for the random forest analysis
were created using the training dataset and independently validated
using the validation cohort. Median dichotomization of mRNA abun-
dance for validation was performed in the samemanner as the median
dichotomization of the training cohort in relevant cases.
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package (v1.0-7). Event status for each subject in the validation dataset
was predicted as a probability for each permutation. If the predicted
probability of survival was N0.5, the patient was predicted to survive.
The survival prediction and known survival status were used to
generate the receiver-operator curve (true positive rate versus the
false positive rate) and extract an AUC value.
Validation of the hybrid approach was carried out using the Hatzis
breast cancer dataset (n = 508) [25]. 50-gene and 100-gene classiﬁers
were created as described previously using theMetabric training cohort
froma pool of 1878 genes (881of the 2759 unique geneswere not in the
Hatzis dataset). Each classiﬁer was tested using the Hatzis dataset and
AUCvalueswere calculated for each permutation as described previous-
ly. For eachof the fourmodels, 39millionpermutationswere carried out
to generate a classiﬁer that predicts survival.
Gene Ontology analysis was conducted using the GoMiner online
database [13]. Correlation amongst mRNA abundance was evaluated
using Spearman's correlation. All data analysis was completed using
the R statistical environment (v3.2.1). Data visualizationwas performed
with the lattice (v0.20-33), latticeExtra (v0.6-26) and BPG (v5.3.9; P'ng
et al. in submission) packages.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygeno.2016.06.002.
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